Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 612

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 612
---
 attendance at meetings of the New Semnur Board and any committees thereof. New Semnur’s employee directors will not receive additional compensation for their service as a director. 375

DIRECTORS AND EXECUTIVE OFFICERS OF NEW SEMNUR AFTER THE BUSINESS COMBINATION The following sets forth certain information, as of the date of this proxy statement/prospectus concerning the persons who are expected to serve as directors and executive officers of New Semnur following the consummation of the Business Combination. Executive Officers and Directors after the Business Combination Upon the consummation of the Business Combination, the business and affairs of New Semnur will be managed by or under the direction of the New Semnur Board. The following table sets forth the name, age and position of each of the expected directors and executive officers of New Semnur following the consummation of the Business Combination as of December 31, 2024.

| Name                             |     | Age |     | Position(s)                                                  |
| Executive Officers:              |     |     |     |                                                              |
| Jaisim Shah                      |     |  65 |     | Chief Executive Officer, President and Director              |
| Henry Ji, Ph.D.                  |     |  61 |     | Executive Chairperson and Director                           |
| Stephen Ma                       |     |  53 |     | Chief Financial Officer, Senior Vice President and Secretary |
| Non-employee Directors:          |     |     |     |                                                              |
| Jay Chun, M.D., Ph.D.(1)         |     |  61 |     | Director                                                     |
| Dorman Followwill(1)(2)(3)       |     |  62 |     | Director                                                     |
| Yue Alexander Wu, Ph.D.(1)(2)(3) |     |  61 |     | Director                                                     |

| (1) | Member of the New Semnur Audit Committee, effective upon the consummation of the Business Combination. |

| (2) | Member of the New Semnur Compensation Committee, effective upon the consummation of the Business Combination. |

| (3) | Member of the New Semnur Nominating and Corporate Governance Committee, effective upon the consummation of the Business Combination. |

Executive Officers Jaisim Shah.Upon consummation of the Business Combination, Mr. Shah will serve as New Semnur’s Chief Executive Officer and President and a member of the New Semnur Board. He